SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors

• Published in: Biomedicine & pharmacotherapy 2024-01, Vol.170, p.115586-115586, Article 115586
• Main Authors: Sun, Qin, Xing, Xiaorui, Wang, Huanyu, Wan, Kang, Fan, Ruobing, Liu, Cheng, Wang, Yongjian, Wu, Wenyi, Wang, Yibing, Wang, Ru
• Format: Article
• Language: English
• Subjects: Metabolic diseases; Metabolic homeostasis; Monounsaturated fatty acids; Saturated fatty acids; Stearoyl-CoA desaturase 1
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.115586

Metabolic diseases, featured with dysregulated energy homeostasis, have become major global health challenges. Patients with metabolic diseases have high probability to manifest multiple complications in lipid metabolism, e.g. obesity, insulin resistance and fatty liver. Therefore, targeting the hub genes in lipid metabolism may systemically ameliorate the metabolic diseases, along with the complications. Stearoyl-CoA desaturase 1(SCD1) is a key enzyme that desaturates the saturated fatty acids (SFAs) derived from de novo lipogenesis or diet to generate monounsaturated fatty acids (MUFAs). SCD1 maintains the metabolic and tissue homeostasis by responding to, and integrating the multiple layers of endogenous stimuli, which is mediated by the synthesized MUFAs. It critically regulates a myriad of physiological processes, including energy homeostasis, development, autophagy, tumorigenesis and inflammation. Aberrant transcriptional and epigenetic activation of SCD1 regulates AMPK/ACC, SIRT1/PGC1α, NcDase/Wnt, etc, and causes aberrant lipid accumulation, thereby promoting the progression of obesity, non-alcoholic fatty liver, diabetes and cancer. This review critically assesses the integrative mechanisms of the (patho)physiological functions of SCD1 in metabolic homeostasis, inflammation and autophagy. For translational perspective, potent SCD1 inhibitors have been developed to treat various types of cancer. We thus discuss the multidisciplinary advances that greatly accelerate the development of SCD1 new inhibitors. In conclusion, besides cancer treatment, SCD1 may serve as the promising target to combat multiple metabolic complications simultaneously. [Display omitted]